You are here
Potential blockbuster therapies, such as proprotein convertase subtilisin/kexin type 9 inhibitors, are expected to revolutionize dyslipidemia treatment and raise global sales.
As researchers seek more-effective, safer medications to treat human immunodeficiency virus, the focus has shifted to fixed-dose, single-tablet combinations.
Available options for Alzheimer’s disease are used only for symptomatic improvement, but disease-modifying therapies may help triple annual medication sales by 2023.
Major depressive disorder is complex and poorly understood; myriad drugs target numerous mechanisms of action. By 2023, sales are expected to reach $7.6 billion.
Future therapies for growth hormone deficiency are expected to include long-acting formulations that may encourage increased use of and adherence to these products.
New medications may soon offer more effective treatments for the approximately 2.5 million patients globally with schizophrenia. Current therapies in 2012 yielded $5.2 billion in global market sales, but by 2022 that is expected to reach $7.9 billion.
As new drugs emerge from the pipeline for the nearly 2 billion patients globally diagnosed with ulcerative colitis and Crohn’s disease, sales of therapies for these conditions are expected to increase from $7.35 billion today to $11.05 billion in 2022.
Global prevalence of type-2 diabetes is expected to reach 330 million cases by 2022, with medication sales of $67.7 billion. The market is crowded with generic medications, and most products now in the development pipeline are “me-too” drugs.
The epilepsy market’s $4.2 billion in global sales in 2012 is expected to increase to $5.4 billion by 2022. In a market crowded with products, pharmaceutical companies have shifted their focus to devising safe adjunctive therapies for refractory patients.
Treatment of Parkinson’s disease is expected to lead to $3.56 billion in global sales in 2022. Manufacturers are reformulating medications in addition to creating new ones.